P09.41 Single agent Bevacizumab in recurrent glioblastoma after a second line chemotherapy with Fotemustine. The Italian Association of Neuro Oncology experience

Bevacizumab is an anti-VEGF antibody used in the treatment of recurrent glioblastoma (GBM). Despite the available literature, few is known about the best schedule to administer this angiogenesis inhibitor: i) early, at the first recurrence, or ii) later, after a second line of chemotherapy. In this...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Gonnelli, A., Cantarella, M., Molinari, A., Villani, G., Lombardi, G., Fabrini, M., Pace, A., Fabi, A., Pasqualetti, F., Rudà, R., Soffietti, R., Paiar, F.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
POSTER PRESENTATIONS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464262/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.297
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items